UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): March 15, 2007
China
Medicine Corporation
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-51379
|
51-0539830
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
24A
Jefferson Plaza, Princeton, New Jersey 08540
|
|
(Address
of principal executive offices)
|
Registrant’s
telephone number, including area code: (732)
438-8866
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01 Other Events.
On
March
15, 2007, the officers and directors of the Registrant executed an agreement
reconfirming that they
will
not sell any shares of the Registrant’s common stock, including any shares which
they may acquire upon exercise of options, in the public market prior to August
8, 2007. During the year following that date, they agreed not to sell more
than
10% of their shares in the public market in any three month period.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
CHINA
MEDICINE CORPORATION
|
|
|
(Registrant)
|
| Date: March
16, 2007 |
|
/s/ Senshan
Yang |
| |
|
| |
Senshan
Yang, Chief Executive Officer
|